Consultant Patrick Poulin Inc., Québec City, Québec, Canada; School of Public Health, Université de Montréal, Montréal, Québec, Canada.
J Pharm Sci. 2024 Nov;113(11):3177-3190. doi: 10.1016/j.xphs.2024.09.002. Epub 2024 Sep 13.
Hypothetical and experimental models of unbound fraction have been proposed to facilitate predicting the hepatic clearance (CL) of drugs from values of intrinsic clearance for the unbound drug (CL) and the well-stirred model (WSM). The hypothetical model (fu) is adjusting the unbound fractions determined in plasma in vitro to estimate the maximum unbound fractions at the hepatocytes if each drug-protein complex in plasma becomes fully dissociated at the membrane by any albumin (ALB)-facilitated hepatic uptake mechanism. The model of fu is also adjusting the unbound fraction for a pH gradient effect across the membrane. Alternatively, the new experimental model (fu) measures the unbound fractions resulting to the dynamic dissociation kinetics from proteins in the presence of plasma and a liver enzyme in an in vitro assay. The objective of this study was to conduct an in-depth analysis of previous CL predictions made with these unbound fractions in a companion manuscript. Furthermore, a new dataset on transporter substrates was also included in this study. Finally, the physiological basis of fu has been redefined to extend its applicability with more drugs. In this case, there are lower concentrations of binding proteins in liver versus plasma that could also explain the higher unbound fractions for that organ. The outcomes associated to additional analyses pointed out that fu, again, generally provided the most accurate predictions of CL because fu has generated superior biases of underpredictions or overpredictions. For slowly metabolized drugs bound to ALB, fu was definitively less accurate than fu. For other drug properties, fu fared better but it was still not generally more accurate than fu. Furthermore, experimental values of fu were sometimes incoherent. For example, drugs bound to alpha-acid glycoprotein (AGP) did not follow the principle of fu (i.e., values of fu did not correlate with values of CL) by contrast to those drugs bound to ALB. Therefore, the current experimental setting for fu might be unsuitable in some circumstances. Overall, this study confirmed that calculated values of fu were as accurate as experimental values of fu and can even be more accurate. A guidance on which unbound fraction to use in the WSM is also provided.
已提出了无结合分数的假设和实验模型,以方便根据未结合药物清除率(CL)和完全混合模型(WSM)的值预测药物的肝清除率(CL)。假设模型(fu)通过任何白蛋白(ALB)促进的肝摄取机制调整在体外血浆中测定的未结合分数,以估计如果血浆中的每个药物-蛋白复合物在膜处完全解离,则在肝细胞中最大的未结合分数。fu 模型还调整了跨膜 pH 梯度效应的未结合分数。或者,新的实验模型(fu)在体外测定中,在存在血浆和肝酶的情况下,测量蛋白质动态解离动力学产生的未结合分数。本研究的目的是在一篇伴随的论文中对以前使用这些无结合分数进行的 CL 预测进行深入分析。此外,本研究还包括了一个新的转运体底物数据集。最后,重新定义了 fu 的生理基础,以扩大其在更多药物中的适用性。在这种情况下,肝脏中结合蛋白的浓度较低,这也可以解释该器官中未结合分数较高的原因。额外分析的结果表明,fu 再次通常提供了更准确的 CL 预测,因为 fu 产生了更好的低估或高估偏差。对于与 ALB 结合的代谢缓慢的药物,fu 肯定不如 fu 准确。对于其他药物特性,fu 表现更好,但它并不总是比 fu 更准确。此外,fu 的实验值有时不一致。例如,与与 ALB 结合的药物不同,与α-酸性糖蛋白(AGP)结合的药物不符合 fu 的原理(即 fu 值与 CL 值不相关)。因此,在某些情况下,当前的 fu 实验设置可能不合适。总体而言,本研究证实,计算的 fu 值与实验的 fu 值一样准确,甚至可能更准确。还提供了在 WSM 中使用哪个无结合分数的指南。